药物疗法_____]_癌，非小细胞肺；药物疗法；方案评价

TC和MVP治疗晚期非小细胞肺癌前瞻随机研究

http://www.100md.com 《齐鲁医学杂志》 2006年第1期

药物疗法,,],癌，非小细胞肺；药物疗法；方案评价,1资料与方法,2结果,3讨论,[参考文献]

     [摘要] 目的评价TC和MVP两种方案治疗晚期非小细胞肺癌(NSCLC)有效率、毒性和生存期。方法68例晚期NSCLC病人随机分为两组:TC组34例,MVP组34例。TC组给予国产紫杉醇(Paclitaxel)175 mg/m2静滴第1天；卡铂(CBP)300 mg/m2静滴第2天。MVP组给予丝裂霉素(MMC)6~8 mg/m2静滴第1天；长春花碱酰胺(VDS)2~3 mg/m2，静滴第1、8天；顺铂(DDP)70~80 mg/m2，静滴第1、2天。两方案均为每周期21 d，每例完成2~4周期。结果 TC组有效率为62%(完全缓解1例，部分缓解20例)，MVP组有效率为26%(完全缓解1例，部分缓解8例)，TC组有效率显著高于MVP组(χ2=8.589，P<0.05)。恶心、呕吐及骨髓抑制为主要化疗反应。MVP组Ⅲ、Ⅳ度恶心、呕吐发生率高于TC组，差异有显著性(χ2=7.503，P<0.01)。Ⅲ、Ⅳ度骨髓抑制MVP组稍高于TC组，但差异无显著性。TC组与MVP组的中位生存期分别为10个月与8个月，1年生存率为47%与20%(χ2=5.321，P<0.05)，2年生存率为17%与6%，3年生存率为2%与0。结论 TC组有效率高于MVP组，且恶心、呕吐和骨髓抑制发生率低，该方案是晚期非小细胞肺癌化疗的较佳方案。

    [关键词] 癌，非小细胞肺；药物疗法；方案评价

    A PROSPECTIVE RANDOMIZED STUDY OF TC AND MVP IN ADVANCED NONSMALL CELL LUNG CANCER

    YU JIE, YI XIMEI, ZHANG NAN

    (Department of Internal Medicine, The Third Peoples Hospital of Qingdao, Qingdao 266041,China)

    [ABSTRACT]ObjectiveTo evaluate the response, adverse effects and life span of TC and NVP therapeutic regimens for nonsmall cell lung cancer (NSCLC).MethodsSixtyeight patients with advanced NSCLC were randomized into two groups: TC group (n=34, paclitaxel 175 mg/m2, d1; carboplatin 300 mg/m2, d2) and MVP group (n=34, mitomycin C 6-8 mg/ m2, d1; vindesine 2-3 mg/m2 d1 and d8; cisplatin 70-80 mg/m2, d1 and d2 ). All patients received two to four courses of chemotherapy. ResultsThe overall response was 62% (21/34) in TC group and 26% (9/34) in MVP group. There was one complete response, 20 partial responses in TC group； one complete response, and eight partial response in MVP group. TC regimen appeared to have a higher objective response with statistical difference between two regimens (χ2=8.589, P<0.05). Major side effects were myelosuppression and nausea/vomiting, especially grade Ⅲ,Ⅳnausea/vomiting were significantly higher in MVP than TC (26% and 3%, χ2=7.503, P<0.01). Grade Ⅲ,Ⅳ myelosuppression was higher in MVP than TC, but with no statistical significance existed in the two groups. Median survival time was 10 months vs eight months, and 1,2,3year survival rates were 47% vs 20% (χ2=5.321, P<0.05),17% vs 6%,2% vs 0, for TC and MVP, respectively.ConclusionTC regimen has a higher response rate and longer survival time, less nausea /vomiting and myelosuppression than MVP regimen. TC regimen is a safe and active regimen for advanced nonsmall cell lung cancer. ......

百拇医药网 http://www.100md.com/html/DirDu/2006/04/25/97/05/05.htm

您现在查看是摘要页，全文长 8235 字符。